secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0000950170-25-067511
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025
---------------------------------------------------------------------

- Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.
- Cash $165.8M as of March 31, 2025 vs $183.3M Dec 31, 2024; runway to end of 2026.
- Net loss Q1 2025 $17.5M ($15.3M Q1 2024); R&D expenses $17.4M vs $13.2M.
- G&A expenses decreased to $4.1M from $5.0M on reduced headcount and facility spend.
- Rezatapopt discovery paper published in Cancer Discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/0000950170-25-067511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/pmvp-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer